IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

NCT07361874 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Mild Autonomous Cortisol Secretion (MACS)
Autonomous Cortisol Secretion (ACS)
Subclinical Cushing's
Mild Autonomous Cortisol Excess

Interventions

PROCEDURE: Intervention 1: Adrenalectomy
DRUG: Intervention 2: Semaglutide

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]